Where Do Your Peptides Come From?

The landscape right now

The peptide market is experiencing something unusual: explosive consumer demand colliding with accelerating regulatory enforcement.

On the demand side, the numbers are staggering. Chinese peptide imports to the United States doubled to $328 million in 2025. Online peptide advertising has increased 678% since 2022. GLP-1 receptor agonists became the most prescribed class of medications in the country. And a growing community of longevity-focused adults began exploring compounds like BPC-157, sermorelin, and NAD+ precursors — often purchasing them through channels that exist in a regulatory gray zone.

On the enforcement side, the FDA has responded with the most aggressive peptide crackdown in agency history:

The July 23–24 hearing: what is actually being decided

Next week — July 23 and 24, 2026 — the FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets at the White Oak Campus in Silver Spring, Maryland, to review seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List.

The 503A Bulks List is the list of ingredients that licensed compounding pharmacies are legally permitted to use when preparing custom prescriptions. If a peptide is on this list, a licensed pharmacist can compound it for an individual patient with a valid physician’s prescription. If it is not on this list, compounding it exists in a legal gray area or is outright prohibited.

For compounds like BPC-157, the 503A Bulks List is currently the only pathway to legal clinical access in the United States.

What the FDA is recommending: In its briefing documents, the FDA proposes that none of the seven peptides be added to the list. The agency cites insufficient human safety data, limited or no human efficacy evidence for the proposed routes of administration, and concerns about how well the substances are characterized.

What this does not mean: The PCAC recommendation is non-binding. It begins a formal rulemaking process that includes public comment periods and takes additional months. A negative recommendation does not immediately criminalize possession or physician prescribing. But it signals the direction the regulatory wind is blowing.

The sourcing problem nobody wants to talk about

Here is the part that should matter to you regardless of what the PCAC decides:

The overwhelming majority of peptides available to consumers in the United States are synthesized in China. This is not a political statement — it is a supply-chain fact. Chinese peptide synthesis laboratories range from world-class pharmaceutical manufacturers to unregulated operations producing research-grade compounds with no quality verification.

When you buy peptides from an online vendor labeled “for research use only — not for human consumption,” you are buying a product that:

• Has no guaranteed purity. Certificates of analysis (COAs) provided by vendors are often generated by the manufacturer, not an independent third party. Some are fabricated entirely.
• Has no guaranteed potency. The actual amount of active compound in the vial may differ significantly from what the label claims.
• Has no guaranteed sterility. Injectable peptides that are not produced under pharmaceutical-grade sterile conditions pose real infection risks.
• Has undergone no regulatory oversight. No one inspected the facility. No one verified the process. No one tested the final product against a standard.

A February 2026 investigation published by STAT News highlighted a striking example: 35 of 36 published studies on BPC-157 are animal-only, and the majority trace back to a single research group with undisclosed conflicts of interest. The compound that millions of people are injecting has almost no independent human clinical verification.

This does not mean BPC-157 does not work. It means we do not yet know — from controlled human trials — whether it does, at what dose, by what route, or with what risks. And in the meantime, most of what people are injecting was synthesized by an unknown lab, shipped across an ocean, and sold by a website that disclaims all responsibility for human use.

What “pharmaceutical grade” actually means

Not all compounding is equal, and understanding the difference can protect your health.

FDA-registered compounding pharmacies (operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act) are required to use USP-standard ingredients, follow cGMP or USP 795/797 standards, operate under state pharmacy board licensing and inspection, prepare prescriptions based on valid physician orders, and maintain auditable records.

Research peptide vendors operating online are typically required to do none of these things.

The difference is not a technicality. It is the difference between a compound that was made in a regulated facility, tested for purity and potency, prepared under sterile conditions, and dispensed with physician oversight — and one that was not.

What this means for you

Our position

Concierge Wellness is not here to tell you whether to use peptides. We are here to make sure you understand what the evidence says, where the gaps are, and what questions to ask before making a medical decision.

On sourcing specifically, our position is simple: if you are putting a compound into your body, you deserve to know what is in it, who made it, and whether anyone checked. That is not a radical stance. It is the minimum standard we would apply to our food, our water, and our medicine. Peptides should not be the exception.

We partner with EllieMD because their model aligns with this standard: licensed U.S. providers, prescription-based access, pharmaceutical-grade sourcing, and ongoing clinical supervision. Not every peptide is available through a licensed provider — and for those that are not, that limitation itself is information worth considering.